India Globalization Capital, Inc. (NYSE: IGC) at the Threshold of a Potential Alzheimer’s Breakthrough
Alzheimer’s is the most ominous and expensive disease in the U.S. IGC is the first and only NYSE MKT-listed pharmaceutical company to develop cannabis-based Alzheimer's therapies IGC’s patent pending phytocannabinoid therapies to enter clinical trials for potential Alzheimer’s breakthrough A pioneer in the development of innovative cannabis-based combination therapies, India Globalization Capital (NYSE MKT: IGC) is creating new classes of phytocannabinoid pharmaceuticals with broad therapeutic applications for both humans and animals. IGC’s pipeline of patent pending therapeutics include treatments for pain, cachexia, neurologic disorders, Parkinson’s and Alzheimer’s disease. IGC plans to enter clinical trials this year on its primary pipeline…